Prostate Cancer Screening : The effect on prostate cancer mortality and incidence
(Prostaatkanker screening: Het effect op de prostaatkanker sterfte en incidentie)
2012-05-16
Doctoral Thesis
| Related Files |
|---|
View PDF Version
(120516_Leeuwen, Pim Johannes van.pdf, 4.4MB) |
|
View PDF Version
(stellingen Van Leeuwen.pdf, 0.0MB) |
At first glance, deciding whether to get the PSA screening test for prostate cancer seems to be pretty straightforward and attractive. It’s a simple blood test that can pick up the prostate cancer long before your symptoms appear. After all, your prostate cancer is earlier treated resulting in cure and better outcome. Therefore prostate cancer screening seems to be suitable for public commercials. However, many of the cancers that will be detected by screening are so slow-growing that might never cause problems during mens life. Moreover, their diagnosis by biopsy, and treatment, might be worse than the disease itself. Therefore, prostate cancer screening looks favourable; however, watch out for the prostate cancer bomb.
Financial support for the reproduction of this thesis was generously funded by the following institutions/companies (alphabetically): Abbot, Amgen, Astellas, Bayer Nederland, Beckman Coulter, Coloplast, Chipsoft, Erasmus University Rotterdam, Eurocept Groep, Ferring, GlaxoSmithKline, IPSEN, J.E. Jurriaanse Stichting, Novartis, Sanofi Aventis, Stichting Urologisch Wetenschappelijk Onderzoek, Stichting Wetenschappelijk Onderzoek Prostaatkanker, Zambon
- cancer
- screening
- mortality
- prostate
- study
- prostate cancer
- death
- control
- number
- patient
- population
- biopsy
- cause
- incidence
- disease
- trial
- control arm
- intervention
- erspc
- diagnosis
